In a recent interview, Wayne Brisbane, M.D., discussed new research, presented at the American Urological Association (AUA) conference, which revealed a 15 percent higher AUC for an emerging AI software in detecting seminal vesicle invasion (SVI) in comparison to prostate MRI alone.
Magnetic resonance imaging (MRI) and prostate-specific membrane-antigen positron emission tomography (PSMA PET) both have limitations with respect to the detection of seminal vesicle invasion (SVI) in prostate cancer, noted Wayne Brisbane, M.D., in a recent interview.
“One of the issues is (MRI) is not super sensitive so if there's a small amount of seminal vesicle invasion, it might not be picked up, especially if the tumor volume is very small. But it's still important because we would risk adjust those patients and change their treatment paradigms,” noted Dr. Brisbane, an assistant professor of urology at the University of California-Los Angeles (UCLA). “ … With PSMA, there (are) other challenges. While molecular imaging is very easy to interpret, there is less spatial resolution between the prostate and the seminal vesicle so interpreting seminal vesicle invasion with PSMA and MRI can be challenging.”
However, in a recent lecture at the American Urological Association (AUA) Annual Meeting, Dr. Brisbane discussed key findings from a new study examining the use of the MRI-based artificial intelligence (AI) software Unfold AI (Avenda Health) for detecting SVI in patients with prostate cancer.
In an initial cohort of 147 men who underwent radical prostatectomy (with a 17 percent incidence of SVI), the researchers found that the AI software provided 92 percent sensitivity, 89 percent specificity and a 95 percent area under the receiver operating characteristic curve (AUC), 15 percent higher than the AUC for MRI alone (80 percent).1
“(This) AI (software) was initially trained on (prostate) tumor volume but has found really impressive accuracy for predicting cancers coming out of the prostate or into the seminal vesicles,” noted Dr. Brisbane.
(Editor’s note: For related content, see “Study: PSMA PET/CT More Advantageous than MRI for Locoregional Staging of Prostate Cancer,” “Researchers Unveil PI-QUAL v2 for Prostate MRI Quality Assessments” and “Study Shows PET MRI Offers Better Detection of Localized Prostate Cancer than mpMRI.”)
For more insights from Dr. Brisbane, watch the video below.
Reference
1. Brisbane W, Priester A, Mota SM, et al. Prediction of seminal vesicle invasion using artificial intelligence prostate cancer risk mapping. J Urology. 2025 May 1. https://doi.org/10.1097/01.JU.0001109868.09667.98.20 . Presented at the American Urological Association (AUA) Annual Meeting April 26-29, 2025, Las Vegas.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.